Takeda Pharmaceutical (TAK) Other Operating Expenses (2019 - 2026)

Takeda Pharmaceutical has reported Other Operating Expenses for 7 years, with the latest figure at $1.3 billion in Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 19.23% year-over-year to $1.3 billion in Q1 2026; TTM through Jun 2026 was -$339.2 million, a 133.93% decrease from a year earlier, with the FY2026 full-year figure at $9.4 billion, down 8.54% from the prior year.
• Other Operating Expenses was $1.3 billion for Q1 2026 at Takeda Pharmaceutical, up from $1.1 billion in the prior quarter.
• The five-year high for Other Operating Expenses was $1.6 billion in Q1 2025, with the low at -$2.7 billion in Q3 2025.
• Average Other Operating Expenses over 5 years is $263.7 million, with a median of $1.1 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Other Operating Expenses increased 17.86% in 2023, then decreased 19.23% in 2026.
• Over 5 years, Other Operating Expenses stood at $1.3 billion in 2022, then retreated by 10.94% to $1.1 billion in 2023, then slipped by 16.99% to $953.0 million in 2024, then climbed by 10.54% to $1.1 billion in 2025, then climbed by 21.56% to $1.3 billion in 2026.
• The last three Other Operating Expenses figures came in at $1.3 billion (Q1 2026), $1.1 billion (Q4 2025), and -$2.7 billion (Q3 2025), per Business Quant data.